Aspira Pathlab & Diagnostics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Aspira Pathlab & Diagnostics has been growing earnings at an average annual rate of 21.4%, while the Healthcare industry saw earnings growing at 29.2% annually. Revenues have been growing at an average rate of 9.2% per year.
Belangrijke informatie
21.4%
Groei van de winst
28.5%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 29.4% |
| Inkomstengroei | 9.2% |
| Rendement op eigen vermogen | -18.8% |
| Nettomarge | -12.5% |
| Volgende winstupdate | 12 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Aspira Pathlab & Diagnostics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 152 | -19 | 0 | 0 |
| 31 Mar 24 | 132 | -27 | 3 | 0 |
| 31 Dec 23 | 128 | -24 | 5 | 0 |
| 30 Jun 23 | 141 | -5 | 0 | 0 |
| 31 Mar 23 | 145 | -1 | 5 | 0 |
| 31 Dec 22 | 165 | 16 | 2 | 0 |
| 30 Sep 22 | 168 | 20 | 2 | 0 |
| 30 Jun 22 | 166 | 22 | 0 | 0 |
| 31 Mar 22 | 195 | 45 | 2 | 0 |
| 31 Dec 21 | 182 | 34 | 4 | 0 |
| 30 Jun 21 | 196 | 40 | 0 | 0 |
| 31 Mar 21 | 152 | 14 | 4 | 0 |
| 31 Dec 20 | 131 | -4 | 5 | 0 |
| 30 Jun 20 | 80 | -38 | 5 | 0 |
| 31 Mar 20 | 84 | -42 | 5 | 0 |
| 30 Sep 19 | 84 | -44 | 9 | 0 |
| 30 Jun 19 | 81 | -49 | 0 | 0 |
| 31 Mar 19 | 76 | -52 | 9 | 0 |
| 31 Mar 18 | 44 | -56 | 8 | 0 |
| 31 Mar 17 | 8 | -27 | 6 | 0 |
| 31 Mar 16 | 0 | 0 | 1 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: 540788 is currently unprofitable.
Groeiende winstmarge: 540788 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 540788 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.4% per year.
Versnelling van de groei: Unable to compare 540788's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 540788 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (30.6%).
Rendement op eigen vermogen
Hoge ROE: 540788 has a negative Return on Equity (-18.82%), as it is currently unprofitable.